BioLineRX Ltd. · TASE:BLRX

BioLineRX — Investor Presentation (July 2010)

39 slides from BioLineRX's investor presentation, July 2010

  1. Slide 1: Company Presentation

    Slide 1: Company Presentation

    Company Presentation July 2010

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u

  3. Slide 3: Table of Contents

    Slide 3: Table of Contents

    Table of Contents • Overview • Lead Clinical Programs – BL-1020 – BL-1040 • Summary 3

  4. Slide 4: Overview

    Slide 4: Overview

    Overview 4

  5. Slide 5: BioLineRx Main Achievements to Date

    Slide 5: BioLineRx Main Achievements to Date

    BioLineRx Main Achievements to Date • Validated business model − Two out-licensing deals with a total value of approximately $650 million plus royalties at double-digit rates • Established strategic relationships with all academic and research institutions in Israel • Two unique early stage programs

  6. Slide 6: BioLineRx at a Glance

    Slide 6: BioLineRx at a Glance

    BioLineRx at a Glance • Founded in 2003 by leaders in Israeli life sciences arena • Market cap ~$120 million (as of July 15, 2010) - symbol “BLRX” • Shareholder breakdown: − Public -73% − Teva Pharmaceuticals - 10% − Others - 17% • 50 employees • Available cash after close of latest transaction - ~$

  7. Slide 7: Management Team

    Slide 7: Management Team

    Management Team Kinneret Savitsky, PhD CEO Former VP R&D at Compugen (NASDAQ: CGEN) Moshe Phillip, MD VP of Clinical/Medical Affairs Vice Dean of TAU Medical School Nir Gamliel VP Business Development, BioLineRx USA, Inc. Former VP, Sales and Marketing, BSP, Ltd., Compugen USA, Inc.; Franchise Manag

  8. Slide 8: Scientific Advisory Board

    Slide 8: Scientific Advisory Board

    Scientific Advisory Board Aaron Ciechanover, MD, PhD Nobel Prize Laureate; Technion Institute Aliza Eshkol, PhD Serono David Ladkani, PhD Teva Pharmaceuticals Moshe Phillip, MD BioLineRx Yaakov Naparstek, MD Hadassah University Hospital Itamar Shalit, MD Schneider Children’s Medical Center Yosef Yar

  9. Slide 9: Company Business Model

    Slide 9: Company Business Model

    Company Business Model • Unique business model focused on “bench to bedside to partner” − Stringent selection and evaluation process − Development through human proof of concept studies − Partnering with pharmaceutical companies to complete clinical development and marketing 9

  10. Slide 10: Company Business Model: Selection and evaluation process

    Slide 10: Company Business Model: Selection and evaluation process

    Company Business Model • Stringent selection and evaluation process – Established strategic relationships with all academic and research institutions in Israel – Close ties with research institutes, academic institutions and biotechnology companies around the world – Use rigorous proprietary evaluat

  11. Slide 11: Company Business Model: Proof of concept and partnering

    Slide 11: Company Business Model: Proof of concept and partnering

    Company Business Model • Development through human proof of concept – Accelerated development programs that meet FDA/EMAE standards – Development through Phase II safety and efficacy studies • Partnering with pharmaceutical companies – Through sub-license agreements – Partner continues clinical deve

  12. Slide 12: Lead Clinical Programs

    Slide 12: Lead Clinical Programs

    Lead Clinical Programs 12

  13. Slide 13: Lead Clinical Compounds: BL-1020

    Slide 13: Lead Clinical Compounds: BL-1020

    Lead Clinical Compounds • BL-1020 for Schizophrenia − Highly efficacious − Enhanced safety profile − First anti-psychotic to show clinically relevant cognitive improvement − Market size for anti-psychotics estimated at $13 billion (US alone) − Potential BL-1020 market penetration of 25% with current

  14. Slide 14: Lead Clinical Compounds: BL-1040

    Slide 14: Lead Clinical Compounds: BL-1040

    Lead Clinical Compounds • BL-1040 for prevention of cardiac remodeling following Acute Myocardial Infarction (AMI) − Efficacy shown in various pre-clinical models − Safe, easy administration − Designated as device by FDA and EMEA − Estimated potential market size of $2-4 billion (worldwide) − Out-li

  15. Slide 15: Lead Clinical Compounds: BL-5010

    Slide 15: Lead Clinical Compounds: BL-5010

    Lead Clinical Compounds • BL-5010 for non-surgical removal of skin lesions − Novel formulation of organic acids in use in cosmetics and dermatology − Easy, convenient treatment − Allows preservation of lesion’s cellular structure; enables subsequent histological examination − Clinical trial ongoing-

  16. Slide 16: BL-1020: First in Class GABA-Enhanced Antipsychotic for Schizophrenia

    Slide 16: BL-1020: First in Class GABA-Enhanced Antipsychotic for Schizophrenia

    BL-1020: First in Class GABA-Enhanced Antipsychotic for Schizophrenia Out-licensed to Cypress Bioscience Inc. 16

  17. Slide 17: BL-1020 Mode Of Action

    Slide 17: BL-1020 Mode Of Action

    BL-1020 Mode Of Action • Schizophrenia involves an imbalance in two key neurotransmitters – Dopamine hyperactivity (many anti-psychotics block dopamine) – GABA hypoactivity (free GABA cannot cross the BBB) • BL-1020 MOA – Dopamine antagonism – GABAergic activity 17

  18. Slide 18: Phase IIb EAGLE Trial Overview

    Slide 18: Phase IIb EAGLE Trial Overview

    Phase IIb EAGLE Trial Overview • Double blind, multi-center, 6-week study • Designed to determine the efficacy, safety and tolerability of BL-1020 in hospitalized patients with acute exacerbation of schizophrenia • Full GCP trial conducted under U.S. FDA IND at 40 sites in the USA, Europe and India

  19. Slide 19: EAGLE Trial Endpoints

    Slide 19: EAGLE Trial Endpoints

    EAGLE Trial Endpoints • Efficacy endpoints comprised the mean change from baseline in the total score of the following:  Primary: − PANSS (Positive and Negative Symptom Scale)  Secondary:: − CGI-S and CGI-C (Clinical Global Impression of Severity or Change) − Readiness to Discharge Questionnaire (

  20. Slide 20: BL-1020 Treatment Leads to Improvement in Cognitive Function

    Slide 20: BL-1020 Treatment Leads to Improvement in Cognitive Function

    BL-1020 Treatment Leads to Clinically Relevant and Statistically Significant Improvement in Cognitive Function Placebo BL-1020 Risperidone 20-30mg BACS (LS mean, 6.01 9.27 6.2 LOCF) P value vs. placebo P=0.027 NS P value vs. P=0.027 Risperidone 20

  21. Slide 21: BL-1020's GABAergic Activity Results in Cognitive Improvement

    Slide 21: BL-1020's GABAergic Activity Results in Cognitive Improvement

    BL-1020’s GABAergic Activity Results in Cognitive Improvement • Cognition is unmet medical need in schizophrenia • In vivo studies show BL-1020 is effective in reversing cognitive impairment • Selective GABAA antagonist studies indicate BL-1020’s effect on cognition is mediated through GABA 21

  22. Slide 22: Out-licensing Deal With Cypress Bioscience

    Slide 22: Out-licensing Deal With Cypress Bioscience

    Out-licensing Deal With Cypress Bioscience • Agreement solely covers US, Canada and Mexico – Cypress manages and finances all future development – Cypress responsible for filing all regulatory applications • BioLineRx retains rights to rest of world (approx 50% of global market) – BioLineRx has righ

  23. Slide 23: Current status and next steps

    Slide 23: Current status and next steps

    Current status and next steps • Scientific Advisory Board meeting held at end of June – Included several key opinion leaders in field of cognition • First Joint Scientific Committee meeting to be held in August • Clinical Advisory Board scheduled to meet in September • Regulatory submissions to be m

  24. Slide 24: BL-1040: First-In-Class Myocardial Implant

    Slide 24: BL-1040: First-In-Class Myocardial Implant

    BL-1040: First-In-Class Myocardial Implant for The Treatment of Tissue Damaged by AMI Out-licensed to Ikaria Holdings Inc. 24

  25. Slide 25: Current Treatment Methodologies and Unmet Medical Need

    Slide 25: Current Treatment Methodologies and Unmet Medical Need

    Current Treatment Methodologies and Unmet Medical Need Vessel occlusion Tissue damage Successfully treated with No current treatment for PCI and stents myocardial damage ? 25

  26. Slide 26: BL-1040: Mechanism and Pathway

    Slide 26: BL-1040: Mechanism and Pathway

    BL-1040: Mechanism and Pathway Infarct related artery (intra-vascular) injection Deposition into infarcted tissue Liquid to gel phase transition upon contact with infarcted tissue Phase transition at infarct area creates resorbable bioprosthetic scaffold providing mechanical support to damaged cardi

  27. Slide 27: BL-1040 is a Disease Modifying Treatment for LV Remodeling

    Slide 27: BL-1040 is a Disease Modifying Treatment for LV Remodeling

    BL-1040 is a Disease Modifying Treatment Addressing Patients at Risk for LV Remodeling 27

  28. Slide 28: BL-1040 Deposits in the Damaged Tissue Following Intra-Coronary Injection

    Slide 28: BL-1040 Deposits in the Damaged Tissue Following Intra-Coronary Injection

    BL-1040 Deposits in the Damaged Tissue Following Intra-Coronary Injection Targeting mechanism: 1. Injection occurs in the infarct related artery 2. Capillary bed compromised secondary to ischemia allows inflow of BL-1040 3. Physiological condition of ischemic region enables liquid to gel transition

  29. Slide 29: BL-1040 Prevents Structural Changes Following AMI

    Slide 29: BL-1040 Prevents Structural Changes Following AMI

    BL-1040 Prevents Structural Changes Following AMI Porcine AMI model, day 60 Dilated left Normal ventricle size left ventricle Thin LV Normal LV wall wall Untreated BL-1040 29

  30. Slide 30: BL-1040 Resorbs Within Six weeks Following Injection

    Slide 30: BL-1040 Resorbs Within Six weeks Following Injection

    BL-1040 Resorbs Within Six weeks Following Injection Microscopic view of labeled BL-1040 (brown biotin staining) distribution in the scar tissue: BL-1040 resorption Alginate resorption inscar in the scar 60 40 % of scar p=0.0007 20 0 0 10 20 30 40 50 Days after injection Landa et al. Circulation 200

  31. Slide 31: Pilot Clinical Trial

    Slide 31: Pilot Clinical Trial

    Pilot Clinical Trial • Clinical program based on extensive interaction with FDA (CDRH division) • Pilot study in Europe – completed January 2010 – 27 patients, safety and preliminary efficacy in patients with primary MI at high risk for LV remodeling • 9 sites: 6 in Germany, 3 in Belgium  Prelimina

  32. Slide 32: BioLineRx-Ikaria BL-1040 Deal

    Slide 32: BioLineRx-Ikaria BL-1040 Deal

    BioLineRx-Ikaria BL-1040 Deal • Total deal value - $282.5 million in upfront and milestones payments – Upfront - $7 million (received) – First milestone – February 2010 - successful completion of pilot study - $10 million (received) – ~$115 million in additional regulatory and developmental mileston

  33. Slide 33: Current Status and Next Steps

    Slide 33: Current Status and Next Steps

    Current Status and Next Steps • Next trials to commence Q111 – Size and location of pivotal trial(s) under discussion – Clinical batch manufacturing ongoing – FDA required pre-clinical studies completed 33

  34. Slide 34: Summary

    Slide 34: Summary

    Summary 34

  35. Slide 35: Highlights: Lead drug shows cognition improvements

    Slide 35: Highlights: Lead drug shows cognition improvements

    Highlights • Lead drug shows cognition improvements in schizophrenia in mid-stage trials – As effective as Risperdal but with better safety in Phase II trials – US partnership with Cypress Bioscience, including $30 million upfront and royalties of 12-18% – ROW is unencumbered and may be partnered in

  36. Slide 36: Highlights: Second program ready for pivotal trials

    Slide 36: Highlights: Second program ready for pivotal trials

    Highlights • Second program ready for pivotal trials – Device intended to prevent ventricular remodeling and congestive heart failure after acute MI – Pilot study in 27 patients showed safety – Partnered worldwide with Ikaria - included upfront payment of $7 million and 11-15% royalties – Pivotal tr

  37. Slide 37: Highlights: Experienced team and attractive valuation

    Slide 37: Highlights: Experienced team and attractive valuation

    Highlights • Experienced drug development team with proven capabilities – Successfully in-licensed over 30 molecules – Advanced most promising through pre-clinical and early clinical trials – Partnered off two leading candidates • Attractive valuation – Currently traded on Tel Aviv Stock Exchange –

  38. Slide 38: Company Milestones Through End of 2012

    Slide 38: Company Milestones Through End of 2012

    Company Milestones Through End of 2012 BL-1040 BL-5010 • Start of pivotal trial • Completion of Phase I/II clinical • Receipt of CE mark trial • Receipt of additional payments • Out-licensing transaction related to regulatory and development milestones OTHER BL-1020 • Start of clinical phase on new

  39. Slide 39: Thank you for your time.

    Slide 39: Thank you for your time.

    Thank you for your time. For more information please visit www.BioLineRx.com

Source: Internet Archive copy of biolinerx.com

More decks from BioLineRX Ltd.

All 37 BioLineRX decks